

## Neonatal Respiratory Morbidity among Late Preterm Births by Planned Mode of Delivery and Gestational Age

Online Supplement

eTable 1: Sample sizes of strata

Week of Gestation at Presentation	Planned Vaginal Delivery n=2,351	Planned Cesarean Delivery n=474
34 weeks	644 (27.4%)	98 (20.8%)
35 weeks	887 (37.7%)	213 (44.9%)
36 weeks	820 (34.9%)	163 (34.3%)

eTable 2: Distribution of patent factors between the control and treatment groups

Factor	Control n=1,399	Treatment n=1,426	P value
Gestational age at randomization (days) <sup>1</sup>	248.4 (5.5)	248.6 (5.4)	0.31
Gestational age at randomization (weeks)			0.21
34 weeks	388 (27.7%)	354 (24.8%)	
35 weeks	534 (38.2%)	566 (26.7%)	
36 weeks	477 (34.1%)	506 (35.5%)	
Planned Mode of Delivery			0.70
Vaginal	1,173 (83.8%)	1,178 (82.6%)	
Cesarean	226 (16.2%)	248 (17.4%)	

<sup>1</sup> Presented as mean (standard deviation).

eTable 3: Observed rates and corresponding 95% confidence intervals of respiratory morbidity among the neonates not exposed and exposed to antenatal steroids, stratified by planned mode of delivery and week of gestation

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	20.5 (16.2-24.8)	17.6 (13.3-21.9)	39.2 (25.6-52.7)	31.9 (18.4-45.4)
35 weeks	12.1 (9.1-15.2)	10.2 (7.4-13.0)	25.8 (17.0-34.5)	12.7 (6.1-18.0)
36 weeks	5.3 (3.1-7.5)	6.2 (3.9-8.5)	16.7 (8.3-25.0)	11.8 (4.9-18.7)

ALPS, antenatal late preterm steroids.

eTable 4: Unadjusted and adjusted risk of respiratory morbidity

Model Term	Unadjusted Risk Ratio (95% CI)	Adjusted Risk Ratio (95% CI)
Treatment Group		
Placebo	Reference	Reference
Antenatal Steroids	0.81 (0.66, 0.98)	0.81 (0.68, 0.97)
Planned Mode of Delivery		
Vaginal	Reference	Reference
Cesarean	1.79 (1.45, 2.20)	1.90 (1.55, 2.33)
Week of Gestation (days)	0.92 (0.91, 0.94)	0.90 (0.90, 0.94)

CI, confidence interval.

eTable 5: Observed rates and corresponding 95% confidence intervals of severe respiratory complications among the neonates not exposed to antenatal steroids, stratified by planned mode of delivery and week of gestation

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS	ALPS	No ALPS	ALPS
34 weeks	15.7 (11.8-19.6)	13.7 (9.8-17.5)	37.3 (23.9-50.7)	23.4 (11.1-35.6)
35 weeks	10.5 (7.6-13.4)	6.2 (4.0-8.5)	23.7 (15.2-32.2)	9.5 (4.1-14.8)
36 weeks	4.3 (2.3-6.2)	3.3 (1.6-5.0)	12.8 (5.4-20.3)	8.2 (2.4-14.1)


ALPS, antenatal late preterm steroids.

eTable 6: Unadjusted and adjusted risk of severe respiratory complications


Model Term	Unadjusted Risk Ratio (95% CI)	Adjusted Risk Ratio (95% CI)
Treatment Group		
Placebo	Reference	Reference
Antenatal Steroids	0.66 (0.53, 0.83)	0.66 (0.53, 0.83)
Planned Mode of Delivery		
Vaginal	Reference	Reference
Cesarean	2.00 (1.58, 2.54)	2.16 (1.71, 2.72)
Week of Gestation (days)	0.92 (0.90, 0.94)	0.92 (0.90, 0.94)

CI, confidence interval.


eFigure 1: Cross-validated receiver operating characteristic curves for model predicting the primary outcome (respiratory morbidity)



eFigure 2: Calibration plot for the model predicting the primary outcome (respiratory morbidity)



eFigure 3: Cross-validated receiver operating characteristic curves for the model predicting the secondary outcome (severe respiratory complications)



eFigure 4: Calibration plot for the model predicting the secondary outcome (severe respiratory complications)

